Parexel Says It Is Ideally Positioned As Big Pharma Shakes Up R&D Efforts
This article was originally published in The Pink Sheet Daily
Executive Summary
Noting its recent five-year contract with Pfizer, the CRO predicts 13% revenue growth for fiscal 2012.
You may also be interested in...
Parexel Outlines Biopharma Advances And Increased Outsourcing
The CRO highlighted industry R&D success and an ever-expanding reliance on outsourcing at its June 26 investor day. Management said there are already more clinical development staff at CROs than within biopharma and suggested that soon more drug development will be done by CROs than drug manufacturers.
In Private Equity Hands, PPD Could Seek More Deals
Two private equity firms’ agreement to acquire Pharmaceutical Product Development Inc. and take the company private is the latest and largest deal in a recent spate of PE activity among contract research organizations – and perhaps not the last, or even least.
In Private Equity Hands, PPD Could Seek More Deals
Two private equity firms’ agreement to acquire Pharmaceutical Product Development Inc. and take the company private is the latest and largest deal in a recent spate of PE activity among contract research organizations – and perhaps not the last, or even least.